Troy– Author –
-
Fluorine-Rich Carbon Quantum Dots Set New Efficiency Benchmarks for CO2-to-Methane Conversion
ResearchGate Unknown Overview Researchers have developed fluorine-rich carbon quantum dots (F1-CQDs) with up to 28.8 at.% fluorine, achieving exceptional performance in the selective electroreduction of CO2 to CH4. This catalyst demonstr... -
Beyond LNPs: Polymer Delivery Systems Promise Enhanced Stability, Reduced Toxicity, and Targeted Delivery for mRNA Therapeutics
MDPI Switzerland Overview Polymer-based delivery systems are rapidly emerging as a promising alternative to conventional lipid nanoparticles (LNPs) for mRNA therapeutics. While LNPs have achieved significant clinical success, particularl... -
Precision Oncology Unleashed: Tumor-Specific Promoters and Nanocarriers Drive Next-Gen Gene Therapy, LNP-Based mRNA/siRNA Therapies Paving the Way
MDPI Switzerland Overview Precision cancer gene therapy is being transformed by the integration of tumor-specific promoters and nanodelivery systems, significantly enhancing therapeutic specificity. A range of nanocarriers, including LNP... -
Unlocking Next-Gen Wearables: Nanocomposites Enhance Chip Embedding for Extreme Environments
PatSnap Eureka Unknown Overview Novel polymer-based nanocomposites are revolutionizing wearable sensor chip embedding by significantly enhancing mechanical, thermal, and barrier properties, paving the way for advanced applications in aer... -
Multi-Walled Carbon Nanotubes Supercharge Li-ion Batteries: 3-10x Performance Boost at Competitive Costs
Cheap Tubes USA Overview Carbon Nanotubes (CNTs) are emerging as transformative conductive additives for lithium-ion batteries, delivering 3-10 times the performance enhancement of traditional carbon black with significantly reduced mate... -
Sana Biotechnology to Announce Q1 Financial Results and Hypoimmune Cell Therapy Pipeline Progress at June Investor Conferences
Stock Titan USA Overview Sana Biotechnology is scheduled to present its Q1 2026 financial results and recent business updates on its hypoimmune cell therapy and in vivo gene editing platforms at multiple investor conferences in June 2026... -
DelveInsight Reports Robust Parkinson’s Disease Pipeline: Over 240 Therapies in Clinical and Preclinical Development
DelveInsight USA Overview DelveInsight's "Parkinson's Disease Pipeline Analysis, 2026" reveals a highly active R&D landscape with over 240 therapies in clinical and preclinical stages. This extensive pipeline spans diverse modalities... -
Japan Reinforces LMO Safety Regulations for Advanced Biotech Research and Regenerative Medicine
厚生労働省 Japan Overview Japan's Ministry of Health, Labour and Welfare (MHLW) has reissued critical guidelines on the contained use (Type 2) of living modified organisms (LMOs) under the Cartagena Act. This re-notification emphasizes s... -
DelveInsight: 180+ Companies Propel CAR-T Innovation, Forging a New Era in Cell Therapy
DelveInsight USA Overview A new DelveInsight report reveals the significant expansion of the CAR-T cell therapy pipeline, with over 180 companies driving innovation. Projecting substantial market growth by 2036, the report highlights key... -
Kelonia Therapeutics’ BCMA-Targeted In Vivo CAR T Therapy KLN-1010 Shows Promise for Multiple Myeloma with Updated Phase 1 ASCO Data
Kelonia Therapeutics Press Release USA Overview Kelonia Therapeutics presented updated first-in-human data from its Phase 1 inMMyCAR study of KLN-1010, a BCMA-targeted in vivo CAR T-cell therapy, at the 2026 American Society of Clinical ...
